Study of XH02 for hypoparathyroidism
Part of Hormones & metabolism clinical trials.
This trial tests an investigational drug called XH02 for people with hypoparathyroidism (low parathyroid hormone) that is not well controlled with standard calcium and vitamin D treatments. The goal is to see if XH02 is safe and effective at managing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had hypoparathyroidism for at least 6 months, caused by surgery, autoimmunity, genetics, or unknown reasons, with low calcium and low parathyroid hormone levels.
- Your current calcium and vitamin D treatment does not work well enough or causes side effects.
- Your body mass index (BMI) is between 17 and 40.
- You do not have other conditions affecting calcium or bone health, such as active thyroid issues, severe diabetes, kidney disease, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called XH-02 for hypoparathyroidism—a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. If you haven't improved with standard calcium and vitamin D treatments, this trial may help.
This study tests whether a new injectable medicine called XH-02 can safely treat hypoparathyroidism—a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. If your calcium isn't well-controlled with current treatments (calcium and vitamin D supplements), this trial might help.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.
Hear when a new Hypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.